KALA Executive Compensation
* In USD (Original Currency)|
Filing Date (SEC Report) |
Year | Reporting Name | Salary | Bonus | Stock Award | Incentive Plan Compensation | Other Compensation | Total |
|---|---|---|---|---|---|---|---|---|
| 2023-05-11 | 2022 | Mark Iwicki Chief Executive Officer | 682,110 | 409,266 | 0 | 0 | 6,120 | 1,868,299 |
| 2023-05-11 | 2021 | Kim Brazzell, Ph.D. Head of Research and Development and Chief Medical Officer | 476,207 | 150,005 | 188,650 | 0 | 18,976 | 1,316,969 |
| 2023-05-11 | 2022 | Kim Brazzell, Ph.D. Head of Research and Development and Chief Medical Officer | 500,000 | 225,000 | 0 | 0 | 25,912 | 993,689 |
| 2023-05-11 | 2021 | Todd Bazemore President and Chief Operating Officer | 489,878 | 171,457 | 188,650 | 0 | 10,240 | 1,343,356 |
| 2023-05-11 | 2022 | Todd Bazemore President and Chief Operating Officer | 515,000 | 257,500 | 0 | 0 | 10,540 | 1,025,817 |
| 2023-05-11 | 2021 | Mark Iwicki Chief Executive Officer | 643,500 | 270,270 | 521,360 | 0 | 6,120 | 2,772,056 |
| 2023-03-13 | 2021 | Todd Bazemore President and Chief Operating Officer | 489,878 | 171,457 | 188,650 | 0 | 10,240 | 1,343,356 |
| 2023-03-13 | 2022 | Mark Iwicki Chief Executive Officer | 682,110 | 409,266 | 0 | 0 | 6,120 | 1,868,299 |
| 2023-03-13 | 2021 | Mark Iwicki Chief Executive Officer | 643,500 | 270,270 | 521,360 | 0 | 6,120 | 2,772,056 |
| 2023-03-13 | 2022 | Todd Bazemore President and Chief Operating Officer | 515,000 | 257,500 | 0 | 0 | 10,540 | 1,025,817 |
| 2023-03-13 | 2022 | Kim Brazzell, Ph.D. Head of Research and Development and Chief Medical Officer | 500,000 | 225,000 | 0 | 0 | 25,912 | 993,689 |
| 2023-03-13 | 2021 | Kim Brazzell, Ph.D. Head of Research and Development and Chief Medical Officer | 476,207 | 150,005 | 188,650 | 0 | 18,976 | 1,316,969 |
| 2022-04-29 | 2020 | Kim Brazzell, Ph.D. Head of Research and Developemnt and Chief Medical Officer | 455,700 | 373,420 | 1,170,000 | 0 | 19,155 | 2,336,604 |
| 2022-04-29 | 2021 | Kim Brazzell, Ph.D. Head of Research and Developemnt and Chief Medical Officer | 476,207 | 150,005 | 188,650 | 0 | 18,976 | 1,316,969 |
| 2022-04-29 | 2020 | Todd Bazemore President and Chief Operating Officer | 455,700 | 273,420 | 1,170,000 | 0 | 10,419 | 2,228,316 |
| 2022-04-29 | 2021 | Todd Bazemore President and Chief Operating Officer | 489,878 | 171,457 | 188,650 | 0 | 10,240 | 1,343,356 |
| 2022-04-29 | 2020 | Mark Iwicki Chief Executive Officer | 585,500 | 676,500 | 2,665,962 | 0 | 4,719 | 4,901,760 |
| 2022-04-29 | 2021 | Mark Iwicki Chief Executive Officer | 643,500 | 270,270 | 521,360 | 0 | 6,120 | 2,772,056 |
| 2021-04-28 | 2020 | Mark Iwicki President and Chief Executive Officer | 585,500 | 676,500 | 2,665,962 | 0 | 4,719 | 4,901,760 |
| 2021-04-28 | 2020 | Todd Bazemore Chief Operating Officer | 455,700 | 273,420 | 1,170,000 | 0 | 10,419 | 2,228,316 |
| 2021-04-28 | 2019 | Todd Bazemore Chief Operating Officer | 440,300 | 158,508 | 0 | 0 | 8,694 | 1,674,106 |
| 2021-04-28 | 2020 | Kim Brazzell, Ph.D. Chief Medical Officer | 455,700 | 373,420 | 1,170,000 | 0 | 19,155 | 2,336,604 |
| 2021-04-28 | 2019 | Kim Brazzell, Ph.D. Chief Medical Officer | 440,300 | 158,508 | 0 | 0 | 15,338 | 1,164,505 |
| 2021-04-28 | 2019 | Mark Iwicki President and Chief Executive Officer | 563,500 | 304,290 | 0 | 0 | 3,353 | 2,556,167 |
| 2020-04-29 | 2019 | Mark Iwicki Chief Executive Officer | 563,500 | 304,290 | 0 | 0 | 3,353 | 2,556,167 |
| 2020-04-29 | 2019 | Todd Bazemore Chief Operating Officer | 440,300 | 158,508 | 0 | 0 | 8,694 | 1,674,106 |
| 2020-04-29 | 2018 | Todd Bazemore Chief Operating Officer | 405,000 | 194,400 | 0 | 0 | 12,950 | 845,458 |
| 2020-04-29 | 2019 | Eric L. Trachtenberg General Counsel and Chief Compliance Officer | 396,600 | 142,776 | 0 | 0 | 107,186 | 1,495,347 |
| 2020-04-29 | 2018 | Eric L. Trachtenberg General Counsel and Chief Compliance Officer | 288,750 | 184,800 | 0 | 0 | 133,691 | 2,416,706 |
| 2020-04-29 | 2018 | Mark Iwicki Chief Executive Officer | 534,681 | 385,000 | 0 | 0 | 7,709 | 3,072,185 |
| 2019-04-12 | 2017 | Mark Iwicki Chief Executive Officer | 500,588 | 387,450 | 0 | 0 | 1,863 | 1,857,577 |
| 2019-04-12 | 2018 | Kim Brazzell, M.D. Chief Medical Officer | 425,386 | 204,200 | 0 | 0 | 14,312 | 1,296,545 |
| 2019-04-12 | 2017 | Kim Brazzell, M.D. Chief Medical Officer | 384,211 | 205,500 | 0 | 0 | 14,580 | 1,184,024 |
| 2019-04-12 | 2018 | Eric L. Trachtenberg | 288,750 | 184,800 | 0 | 0 | 133,691 | 2,416,706 |
| 2019-04-12 | 2018 | Mark Iwicki Chief Executive Officer | 534,681 | 385,000 | 0 | 0 | 7,709 | 3,072,185 |
| 2018-04-25 | 2017 | Todd Bazemore | 46,731 | 190,000 | 0 | 0 | 971 | 2,997,475 |
| 2018-04-25 | 2017 | Mark Iwicki Chief Executive Officer | 500,588 | 387,450 | 0 | 0 | 1,863 | 1,470,127 |
| 2018-04-25 | 2017 | Kim Brazzell, M.D. Chief Medical Officer | 384,211 | 205,500 | 0 | 0 | 2,119 | 966,063 |
| 2018-04-25 | 2016 | Kim Brazzell, M.D. Chief Medical Officer | 340,973 | 141,750 | 0 | 0 | 1,710 | 859,488 |
| 2018-04-25 | 2016 | Mark Iwicki Chief Executive Officer | 472,738 | 254,300 | 0 | 0 | 1,298 | 2,261,867 |
Disclaimer: The data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by our third party API www.financialmodellingprep.com, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore, Discounting Cash Flows Inc. doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Discounting Cash Flows Inc. or anyone involved with Discounting Cash Flows Inc. will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
